Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00643617 · ClinicalTrials.gov registry record · NA
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
A NA study of Prostate Cancer and Prostatic Neoplasms, sponsored by Accuray Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 307
- Enrollment target
- 18
- Study locations
NCT00643617 is a NA study of Prostate Cancer and Prostatic Neoplasms that has completed, run by Accuray Incorporated. The registered enrollment target is 307 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (50% lower). The trial reports 18 study locations across 12 states.
The verdict
NCT00643617, a NA study of Prostate Cancer and Prostatic Neoplasms, has completed, sponsored by Accuray Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 307 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.
Conditions Studied
Interventions
- RADIATION CyberKnife Stereotactic Radiosurgery - Low Risk
- RADIATION CyberKnife Stereotactic Radiosurgery - Intermediate Risk
Study Locations (18)
California
- Community Regional Medical Center - Fresno
- Long Beach Memorial Medical Center - Long Beach
- Pasadena Cyberknife Center - Pasadena
- CyberKnife Centers of San Diego - San Diego
Florida
- New Millenium CyberKnife - Brandon
- JFK Comprehensive Cancer Center - Lake Worth
- South Florida Radiation Oncology - Wellington
Colorado
- Penrose Cancer Center - Colorado Springs
- Colorado Cyberknife - Lafayette
Alabama
- Mitchell Cancer Center University of South Alabama - Mobile
Illinois
- Elmhurst Memorial Hospital - Elmhurst
Montana
- Benefis Health System - Sletten Cancer Institute - Great Falls
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
New Jersey
- AtlantiCare Regional Medical Center - Egg Harbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2007-10-22 |
| Est. Completion | 2022-04-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00643617
The ClinicalTrials.gov registry entry for NCT00643617 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (50% lower). The listed sponsor is Accuray Incorporated, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which CyberKnife Stereotactic Radiosurgery - Low Risk is the first listed.
NCT00643617 reports 18 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00643617 about?
NCT00643617 is a clinical study titled "CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry". The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.
What is the current status of trial NCT00643617?
This trial is currently completed. It is a NA study. The enrollment target is 307 participants. The study started on 2007-10-22. Estimated completion is 2022-04-07.
What conditions does trial NCT00643617 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostatic Neoplasms, Cancer of the Prostate, Prostatic Cancer, Prostate Neoplasms.
What interventions are being tested in trial NCT00643617?
The interventions under investigation include: CyberKnife Stereotactic Radiosurgery - Low Risk (RADIATION), CyberKnife Stereotactic Radiosurgery - Intermediate Risk (RADIATION).
Who is sponsoring clinical trial NCT00643617?
This trial is sponsored by Accuray Incorporated, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00643617 being conducted?
This trial has 18 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.